← Back to patent-cliff list
FHD-286
Tier C — Watch / tradeFHD-286
Foghorn Therapeutics Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：SMARCA4, SMARCA2
Indications (approved)：Small cell lung cancer, Myelodysplastic syndrome, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, Haematological malignancy, 葡萄膜黑素瘤
Regional status
US
Phase II
2026-09-04
EU
Discontinued
2021-05-11
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of FHD-286?
Approved indications include: Small cell lung cancer, Myelodysplastic syndrome, Acute myeloid leukaemia, Chronic myelomonocytic leukaemia, Haematological malignancy, 葡萄膜黑素瘤.
When does the FHD-286 patent expire?
No public expiry year is available for FHD-286 yet; this page updates once verified.
How do I get a quote for FHD-286 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-22